Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 12,312

Document Document Title
WO/2016/145142A1
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...  
WO/2016/144918A1
A compound of the structure (A), or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.  
WO/2016/014927A3
Provided are crystalline forms of nicotinamide riboside, including a Form I of nicotinamide riboside chloride according to formula (I). Also disclosed are pharmaceutical compositions comprising the crystalline Form I of nicotinamide ribo...  
WO/2016/144660A1
Provided are crystalline forms of nicotinamide riboside, including a Form II of nicotinamide riboside chloride: nicotinamide riboside chloride. Also disclosed are pharmaceutical compositions comprising the crystalline Form II of nicotina...  
WO/2016/140616A1
Compound 1 with the formula I is an HCV antiviral protide, which is surprisingly soluble in ethanol, thereby facilitating the preparation of pharmaceutical formulations, such as adsorbed mesoporous carriers or SEDDS of Pouton Types III o...  
WO/2016/140615A1
Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral sele...  
WO/2016/138035A1
Methods of conjugating oligonucleotides are provided. The methods may include: activating a terminal of first oligonucleotide using a squarate reagent to produce an activated first oligonucleotide; and binding the first oligonucleotide a...  
WO/2016/135582A1
Compounds of the general Formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.  
WO/2016/138026A1
Compositions and methods in the field of medicine and chemistry are disclosed. Some of the disclosed embodiments are directed to nucleotide compounds, medicinal compositions, as well as processes for their preparation and methods of thei...  
WO/2016/134056A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/134054A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/134053A1
The present invention features compounds of e.g. formula I effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HCV ...  
WO/2016/134057A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/134051A1
The present invention features compounds of e.g. formula I effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HCV ...  
WO/2016/108930A3
Provided are antisense oligonucleotides targeted against bacterial genes involved in biochemical pathways and/or cellular processes, and related compositions and methods of using the oligonucleotides and compositions, alone or in combina...  
WO/2016/130691A1
Disclosed herein is a method for treating heart failure in a subject in need thereof. The method includes administering a therapeutically effective amount of nicotinamide riboside to the subject. The heart failure may be associated with ...  
WO/2016/099982A3
Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.  
WO/2016/126734A1
Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including t...  
WO/2015/144282A8
The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.  
WO/2016/120403A1
The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to ...  
WO/2016/123397A2
The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs may show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tau...  
WO/2016/120305A1
A compound of formula (I) Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of sai...  
WO/2016/094677A3
The invention features a mononucleotide comprising a nucleobase bonded to a sugar having a 3'-carbon and a 5'-carbon, where the 5'-carbon is bonded to a phosphorus (V) atom of a phosphate group through an oxygen atom, the phosphorus (V) ...  
WO/2016/112746A1
Disclosed in the present invention is a method for preparing ribofuranose phosphate derivatives, and the preparation steps thereof comprises: coupling starting materials of isopropyl L-alanine hydrochloride, phenol dichlorophosphate and ...  
WO/2016/113335A1
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal...  
WO/2016/110761A1
An efficient and simple process is provided for producing 1-β-D-arabinofuranosylcytosine or cytarabine wherein cytidine hydrochloride is converted to the corresponding 2,2'- anhydro-1-β-D-arabinofuranosylcytosine hydrochloride by react...  
WO/2016/107289A1
The present invention relates to a method for preparing Sofosbuvir crystal form-6. The method is simple in operation, stable in process condition, good in reproducibility, high in yield rate and high in purity, viscous gel-type products ...  
WO/2016/105449A1
This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibro...  
WO/2004/094345A8
This invention relates to protected monomers for the synthesis of iRNA agents.  
WO/2016/101782A1
An oxidized β-nicotinamide adenine dinucleotide phosphate and a purification method therefor, specifically comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a...  
WO/2016/106050A1
This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.  
WO/2016/101412A1
Disclosed are a crystallization water-free calcium dibutyryladenosine cyclophosphate crystal form, and a preparation method and a use thereof. In an X-ray powder diffraction pattern using Cu-Kα as a source of radiation, the crystallizat...  
WO/2016/100569A1
Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus infection with one or more nucleosides, nucleotides and nucl...  
WO/2016/097173A1
A process for preparing a crystalline form of sofosbuvir having an X-ray powder diffraction pattern comprising no reflection at 2-theta angles in the range of from 2.0 to 7.8°, wherein polyethylene glycol is used as additive for solvent...  
WO/2016/100441A1
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.  
WO/2016/098028A1
The disclosure relates to nucleic acids that contain modifications at the 5'-end, 3'-end or 5'-end and 3'-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved exp...  
WO/2016/023522A3
The present invention is directed to Compounds of Formula (I) and salts thereof, wherein R1, R2, R3 and R4 are defined above herein. The present invention is also directed to uses of the compounds of Formula (I) to add phosphoramidate gr...  
WO/2016/100893A1
Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or o...  
WO/2016/100864A1
The present invention provides a method of determining whether cytosine residues present at a predetermined positions within a singl strand of a double stranded DNA of known sequence are methylated as well as compounds for carrying out t...  
WO/2016/094677A2
The invention features a mononucleotide comprising a nucleobase bonded to a sugar having a 3'-carbon and a 5'-carbon, where the 5'-carbon is bonded to a phosphorus (V) atom of a phosphate group through an oxygen atom, the phosphorus (V) ...  
WO/2016/091119A1
Disclosed is a method for purifying oxidized β-nicotinamide adenine dinucleotide, comprising the steps: using a filter membrane to perform microfiltration and nanofiltration on a reaction liquid obtained from an enzyme catalysis reactio...  
WO/2016/091698A1
The present invention relates to compounds of formula (I), wherein R1, R2and R3are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds ...  
WO/2016/091236A1
The present invention provides 6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein Gly represents β-D-arabinofuranosyl or...  
WO/2016/091235A1
The present invention provides 6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein Gly represents β-D-arabinofuranosyl or...  
WO/2016/091121A1
Disclosed is a method for purifying reduced β-nicotinamide adenine dinucleotide, comprising the steps: performing microfiltration and then nanofiltration on a reaction liquid obtained from an enzyme catalysis reaction, and collecting th...  
WO/2016/086860A1
Disclosed is a purification method for β-nicotinamide mononucleotide, comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a pre-treated β-nicotinamide mononucl...  
WO/2016/090005A1
The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.  
WO/2016/083830A1
The present invention relates to chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositi...  
WO/2016/078582A1
Novel nucleoside phosphoramidate derivatives and applications thereof are disclosed. The derivatives are compounds as represented by formula (I) or pharmaceutically acceptable acidic salts, solvates or hydrates thereof, wherein R1 is C1-...  
WO/2016/078397A1
Disclosed are a new type of cytidine derivative, having the general formula (I), and an application thereof. The new type of cytidine derivative of the present invention has a growth inhibitory effect, confirmed by testing, on transplant...  

Matches 401 - 450 out of 12,312